|
|
| | Mapracorat Basic information |
| Product Name: | Mapracorat | | Synonyms: | BAY-865319);BOL 303242X;Mapracorat
(ZK 245186;CS-2895;Mapracorat;ZK 245186;(2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[[(2-methylquinolin-5-yl)amino]methyl]pentan-2-ol;7-Benzofuranpropanol, 5-fluoro-2,3-dihydro-γ,γ-dimethyl-α-[[(2-methyl-5-quinolinyl)amino]methyl]-α-(trifluoromethyl)-, (αR)- | | CAS: | 887375-26-0 | | MF: | C25H26F4N2O2 | | MW: | 462.49 | | EINECS: | | | Product Categories: | | | Mol File: | 887375-26-0.mol |  |
| | Mapracorat Chemical Properties |
| Boiling point | 602.1±55.0 °C(Predicted) | | density | 1.316±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 50.6 mg/mL (109.41 mM) | | form | Solid | | pka | 11.75±0.29(Predicted) | | color | Light yellow to yellow |
| | Mapracorat Usage And Synthesis |
| Uses | Mapracorat is a novel non-steroidal selective glucocorticoid receptor agonist. | | Definition | ChEBI: Mapracorat is an aminoquinoline. | | in vivo | Intradermal injection of compound 48/80 (50 μg in 50 μL saline) resulted in a clear wheal and flare reaction over the 60 min observation period. Topical pre-treatment with mapracorat (0.1%) leads to significant reduction in the wheal and flare responses compared to vehicle (acetone) treated areas. | | References | [1] Bumer W , et al. The selective glucocorticoid receptor agonist mapracorat displays a favourable safety-efficacy ratio for the topical treatment of inflammatory skin diseases in dogs. Vet Dermatol. 2017 Feb; 28(1):46-e11. DOI:10.1111/vde.12315 |
| | Mapracorat Preparation Products And Raw materials |
|